Keywords: Other Neurodegeneration, Neurodegeneration
Motivation: RBD is a prodromal symptom of Parkinson's disease, and DAT-PET aids in diagnosis. However, its accessibility is limited, and SMwI has not been studied as a screening tool.
Goal(s): This study aims to evaluate how accurately SMwI predicts presynaptic dopaminergic function in RBD patients, addressing a critical gap in current research.
Approach: A review of RBD patients diagnosed by polysomnography was conducted, with all undergoing MRI, DAT-PET, and SMwI comparison analysis
Results: In 64 patients, DAT-PET showed decreased uptake in 56.3%, with SMwI missing 15.6% of these. SMwI detected abnormalities in 6.3% not found by DAT-PET, with 72.2% sensitivity and 85.7% specificity.
Impact: In RBD patients, nigrosome 1 evaluation using SMwI showed moderate agreement with DAT PET. However, SMwI's diagnostic sensitivity was lower than in Parkinson’s disease, indicating it may not sufficiently replace DAT PET in RBD diagnosis.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords